Overview

Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, randomized, double-blind, multi-center clinical study to evaluate efficacy and safety of a maintenance therapy with the immunomodulator MGN1703 compared to placebo control. The study will be conducted in patients with advanced colorectal carcinoma (AJCC Stage IV) with disease control after first-line standard chemotherapy regimens.
Phase:
Phase 2
Details
Lead Sponsor:
Mologen AG
Treatments:
Adjuvants, Immunologic
Immunologic Factors